Considering that MDD is accompanied by activation of immuno-inflammatory pathways, oxidative stress, and BDNF reduction, the combination of both pharmacophore groups in MPI can be a promising alternative to treat this disorder (Maes et al., 2012; Moylan et al., 2013; Slyepchenko et al., 2016). This evidence concerns the gene BDNF and major depressive disorder.